Form 8-K - Current report:
SEC Accession No. 0001564590-22-018241
Filing Date
2022-05-05
Accepted
2022-05-05 16:05:41
Documents
13
Period of Report
2022-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atra-8k_20220505.htm   iXBRL 8-K 38478
2 EX-99.1 atra-ex991_6.htm EX-99.1 297642
  Complete submission text file 0001564590-22-018241.txt   484870

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20220505.xsd EX-101.SCH 5693
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20220505_lab.xml EX-101.LAB 19424
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20220505_pre.xml EX-101.PRE 11584
7 EXTRACTED XBRL INSTANCE DOCUMENT atra-8k_20220505_htm.xml XML 3572
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 22896143
SIC: 2836 Biological Products, (No Diagnostic Substances)